111Indium labeled chimeric monoclonal antibody G250

N/A

Report date: 2025/11/17 17:57:26

Base Information

Drug Name111Indium labeled chimeric monoclonal antibody G250

Drug Alias Name111In-cG250In-111-cG250

ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-Carbonic anhydrase IX

TargetsCarbonic anhydrase IX

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesRadboud University Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRadboud University Medical Center

Active IndicationsN/A

Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A